This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Options Traders Expect Huge Moves in AveXis (AVXS) Stock
by Zacks Equity Research
AveXis (AVXS) needs investors to pay close attention to the stock based on moves in the options market lately.
Novartis (NVS) Beats Earnings and Revenue Estimates in Q1
by Zacks Equity Research
Novartis reported encouraging results for the first quarter as sales and earnings both topped expectations on Cosentyx and Entresto strength.
Do Options Traders Know Something About AveXis (AVXS) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to AveXis (AVXS) stock based on the movements in the options market lately.
Agios Pharmaceuticals Shares Rise on Buyout Speculation
by Zacks Equity Research
Agios (AGIO) share price shoots up on probable acquisition by other biggies in the biotech industry. This optimism follows the news of Novartis striking a deal to buy gene therapy company, AveXis.
Company News For Apr 10, 2018
by Zacks Equity Research
Companies in the news are: PME,CBS,WATT,AVXS,NVS
AveXis (AVXS) Enters Overbought Territory
by Zacks Equity Research
AveXis, Inc. (AVXS) has moved higher as of late, but there could definitely be trouble on the horizon for this company
Novartis Inks $8.7 Billion Gene Therapy Deal to Buy AveXis
by Zacks Equity Research
Novartis (NVS) signs a contract to purhcase the U.S. based clinical stage gene therapy company, AveXis, Inc for a cash-tender offer of $218 per share.
Why AveXis (AVXS) Could Be Positioned for a Slump
by Zacks Equity Research
AveXis (AVXS) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
AveXis (AVXS) Jumps: Stock Rises 7.1%
by Zacks Equity Research
AveXis, Inc.(AVXS) was a big mover last session, as the company saw its shares rise over 7% on the day.
AveXis (AVXS) Surges: Stock Moves 5% Higher
by Zacks Equity Research
AveXis (AVXS) was a big mover last session, as the company saw its shares rise over 5% on the day.
What Falling Estimates & Price Mean for AveXis, Inc. (AVXS)
by Zacks Equity Research
It seems wise to sell the AveXis, Inc. (AVXS) stock at this moment as its both estimates and price have been witnessing downward revision.
AveXis, Inc. (AVXS) Looks Good: Stock Moves 15.4% Higher
by Zacks Equity Research
AveXis, Inc. (AVXS) shares rise above 15% in the last trading session.
Will 2017 IPO Market Revive After Dismal 2016?
by Zacks Equity Research
Proceeds from the U.S. Initial Public Offerings (IPOs) slowed down in 2016, as 105 IPOs raised only $18.8 billion, which was the lowest since 2003.